DIAGNOSTIC VALUE OF SERUM N-TERMINAL PRO B-TYPE NATRIURETIC PEPTIDE (NT-PROBNP) FOR LEFT VENTRICULAR DYSFUNCTION IN HYPERTENSIVE CASES.
Objective: Left ventricular hypertrophy (LVH) is an independent risk factor for all cardiovascular complication of Hypertension, in this group early detection is very important for better management. Therefore, the aim of our study is to evaluate cardiac markers in hypertension with LVH.
Material and Methods: The study comprised of 95 patients with the evidence of Hypertension. These cases were further divided into 2 groups i.e. Hypertension without LVH and Hypertension with LVH groups. We assessed blood pressure, electrocardiography and echocardiography. All the cardiac markers are assessed by using ELISA.
Results: In the cases of LVH with hypertension group, the serum cardiac parameter like NTpro-BNP was significantly raised. However, the serum myoglobin and CK-MB did not showed any significant rise when compared with control. In the cases of LVH without hypertension, all these three parameters not have shown any significant raise when compared with control.
Conclusion: Apart from imaging techniques the assessment of serum NT- pro BNP act as better marker for identifying LVH than the traditional markers like CK-MB, myoglobin.
Key words: Hypertension, Left Ventricular Hypertrophy, NTpro-BNP, CK-MB and myoglobin.
2. Devereux RB, Casale PN, Eisenberg RR, Miller DH, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy using echocardiographic determination of left ventricular mass as the reference standard. Comparison of standard criteria, computer diagnosis and physician interpretation. J Am Coll Cardiol 1984;3(1):82-7.
3. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, et al. The heart in hypertension. N Engl J Med 1992;327(14):998-1008.
4. Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ 2006;175(6):611-7.
5. Kroll MH, Srisawasdi P. The clearance of BNP modeled using the NT-proBNP-BNP relationship. Biosystems 2007;88(1-2):147-55.
6. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003;338(1-2):107-15.
7. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362(9380):316-22.
8. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006;92(6):843-9.
9. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: Relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005;46(4):610-20.
10. Wiese S, Breyer T, Dragu A, Wakili R, Burkard T, Schmidt-Schweda S, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: Influence of angiotensin II and diastolic fiber length. Circulation 2000;102(25):3074-9.
11. Gomathi R, Vijipriya M, Usha K. Cardioprotective effect of ethanol extract of Medicago sativa stem on isoproterenol induced myocardial infarction in wistar albino rat. Int J Pharm Pharm Sci 2014;6 Suppl 2:839-42.
12. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949;37(2):161-86.
13. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995;25(4):879-84.
14. Apple FS, Christenson RH, Valdes RJ, Andriak AB, Show-Hong D, Feng YJ, et al. Simultaneous rapid measurement of whole blood myoglobin, creatinine kinase MB and cardiac troponin I by triage cardiac panel for detection of myocardial infarction. Clin Chem 1999;45(2):199-205.
15. Adams JE, Schechtman KB, Landt Y, Ladenson JH, Jaffe AS. Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. Clin Chem 1994;40:1291-5.
16. Raju DS, Patnala K. Elucidating the role of cardiac biomarkers in chronic kidney disease. IAJPR 2015;5(9):3013-23.
17. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of stretching. Endocrinology 1993;132(5):1961-70.
18. DeFilippi CR, Fink JC, Nass CM, Chen H, Christenson R. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 2005;46(1):35-44.
19. Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 2004;6(1):63-70.
20. Morillas P, Castillo J, Quiles J, NuÃ±ez D, GuillÃ©n S, Maceira A, et al. Usefulness of NT-proBNP level for diagnosing left ventricular hypertrophy in hypertensive patients. A cardiac magnetic resonance study. Rev Esp Cardiol 2008;61(9):972-5.
21. Andrade H, Morillas P, Castillo J, RoldÃ¡n J, Mateo I, Agudo P, et al. Diagnostic accuracy of NT-proBNP compared with electrocardiography in detecting left ventricular hypertrophy of hypertensive origin. Rev Esp Cardiol 2011;64(10):939-41.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.